Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ).
Hansoh Pharmaceutical Group Company Limited announced a license agreement with Glenmark Specialty S.A. for the development and commercialization of Aumolertinib in various global regions. This agreement, which includes upfront and potential milestone payments exceeding US$1 billion, along with tiered royalties, is expected to enhance Hansoh’s market presence and expand its reach in the oncology sector.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$48.20 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on innovative drug development. Its primary product, Aumolertinib, is a third-generation EGFR-TKI used for treating non-small cell lung cancer (NSCLC).
Average Trading Volume: 8,425,021
Technical Sentiment Signal: Buy
Current Market Cap: HK$260.4B
For a thorough assessment of 3692 stock, go to TipRanks’ Stock Analysis page.